FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113453730> ?p ?o ?g. }

• W2113453730 endingPage "133" @default.
• W2113453730 startingPage "125" @default.
• W2113453730 abstract "An investigation was conducted to assess the chemopreventive effects of 2-(allylthio)pyrazine (2-AP), synthesized for potential use as a chemopreventive agent, after administration during the pre-initiation and post-initiation stages in a rat colon carcinogenesis model with azoxymethane (AOM). One hundred, 5-week-old, male F344 rats were randomly divided into two experiments (n=50 each). Experiment 1 rats were randomly divided into three groups: Group 1 rats were pre-treated with 2-AP (25 or 50 mg/kg body weight, 3 consecutive days through the route of intragastric intubations) before AOM (20 mg/kg body weight, single subcutaneous (s.c.) injection) initiation. Group 2 rats were treated with AOM alone. Group 3 rats were given 2-AP alone without AOM initiation. The animals were killed at the end of each experiment (week 5) and the aberrant crypt foci (ACF) of the colonic mucosa were assessed after staining with methylene blue. Experiment 2 rats were randomly divided into three groups: Group 1 rats were given 2-AP (10, 25 or 50 mg/kg body weight, five-times intragastric intubations per week for 5 weeks from week 3) after AOM (15 mg/kg body weight, three s.c. injections) initiation for 2 weeks. Group 2 rats were treated with AOM alone. Group 3 rats were given 2-AP alone without AOM initiation. The animals were killed at the end of the experiment (week 8) and the ACF of the colonic mucosa were quantified. Total numbers of ACF/colon in Group 1 rats (pre-treated with 2-AP) tended to decrease (2-AP, 50 mg/kg body weight) or increase (2-AP, 100 mg/kg body weight) depending on the dose level. Total numbers of ACF/colon in Group 1 rats (treated with AOM followed by 2-AP, all subgroups; 160.8±38.0; 161.8±38.1; 137.1±48.4) were decreased significantly compared with the values in Group 2 rats (AOM alone; 214.8±48.1) (P<0.05 or 0.01). The highest dose group (2-AP, 50 mg/kg body weight) had the lowest levels of total numbers of ACF/colon among the three subgroups. Total numbers of aberrant crypts (AC)/colon of the highest dose group (340.1±117.9) decreased significantly compared with the value for Group 2 rats (AOM alone; 545.1±38.3). These results thus suggest that 2-AP may have potential as a chemopreventive agent against rat colon carcinogenesis after administration of AOM during the post-initiation stage." @default.
• W2113453730 created "2016-06-24" @default.
• W2113453730 creator A5047730319 @default.
• W2113453730 creator A5048406337 @default.
• W2113453730 creator A5051286320 @default.
• W2113453730 creator A5061532156 @default.
• W2113453730 creator A5061810491 @default.
• W2113453730 creator A5078098236 @default.
• W2113453730 creator A5081452501 @default.
• W2113453730 creator A5087716966 @default.
• W2113453730 date "2001-05-01" @default.
• W2113453730 modified "2023-10-14" @default.
• W2113453730 title "Chemopreventive effect of 2-(allylthio)pyrazine (2-AP) on rat colon carcinogenesis induced by azoxymethane (AOM)" @default.
• W2113453730 cites W1492846117 @default.
• W2113453730 cites W1552865668 @default.
• W2113453730 cites W1556877038 @default.
• W2113453730 cites W1584378357 @default.
• W2113453730 cites W1679033514 @default.
• W2113453730 cites W1777625438 @default.
• W2113453730 cites W1919257848 @default.
• W2113453730 cites W1924496013 @default.
• W2113453730 cites W1974784612 @default.
• W2113453730 cites W1975799987 @default.
• W2113453730 cites W1991209323 @default.
• W2113453730 cites W2005032123 @default.
• W2113453730 cites W2012948713 @default.
• W2113453730 cites W2016549018 @default.
• W2113453730 cites W2020641997 @default.
• W2113453730 cites W2025054234 @default.
• W2113453730 cites W2029031988 @default.
• W2113453730 cites W2030312997 @default.
• W2113453730 cites W2030736030 @default.
• W2113453730 cites W2030746244 @default.
• W2113453730 cites W2036386519 @default.
• W2113453730 cites W2045555964 @default.
• W2113453730 cites W2049540980 @default.
• W2113453730 cites W2050067824 @default.
• W2113453730 cites W2052899635 @default.
• W2113453730 cites W2053117633 @default.
• W2113453730 cites W2063065212 @default.
• W2113453730 cites W2063087703 @default.
• W2113453730 cites W2066504626 @default.
• W2113453730 cites W2081342061 @default.
• W2113453730 cites W2091295079 @default.
• W2113453730 cites W2103938092 @default.
• W2113453730 cites W2105598170 @default.
• W2113453730 cites W2106633276 @default.
• W2113453730 cites W2116038814 @default.
• W2113453730 cites W2120417804 @default.
• W2113453730 cites W2126472654 @default.
• W2113453730 cites W2130092087 @default.
• W2113453730 cites W2140979026 @default.
• W2113453730 cites W2170130849 @default.
• W2113453730 cites W2171379519 @default.
• W2113453730 cites W2237596531 @default.
• W2113453730 cites W2290370864 @default.
• W2113453730 cites W2313501132 @default.
• W2113453730 cites W2402538701 @default.
• W2113453730 cites W2462442536 @default.
• W2113453730 cites W261715122 @default.
• W2113453730 cites W1999920457 @default.
• W2113453730 doi "https://doi.org/10.1016/s0304-3835(01)00408-6" @default.
• W2113453730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/11311484" @default.
• W2113453730 hasPublicationYear "2001" @default.
• W2113453730 type Work @default.
• W2113453730 sameAs 2113453730 @default.
• W2113453730 citedByCount "3" @default.
• W2113453730 crossrefType "journal-article" @default.
• W2113453730 hasAuthorship W2113453730A5047730319 @default.
• W2113453730 hasAuthorship W2113453730A5048406337 @default.
• W2113453730 hasAuthorship W2113453730A5051286320 @default.
• W2113453730 hasAuthorship W2113453730A5061532156 @default.
• W2113453730 hasAuthorship W2113453730A5061810491 @default.
• W2113453730 hasAuthorship W2113453730A5078098236 @default.
• W2113453730 hasAuthorship W2113453730A5081452501 @default.
• W2113453730 hasAuthorship W2113453730A5087716966 @default.
• W2113453730 hasConcept C121608353 @default.
• W2113453730 hasConcept C126322002 @default.
• W2113453730 hasConcept C134018914 @default.
• W2113453730 hasConcept C147583825 @default.
• W2113453730 hasConcept C2776390293 @default.
• W2113453730 hasConcept C2778452354 @default.
• W2113453730 hasConcept C2779107934 @default.
• W2113453730 hasConcept C2780669762 @default.
• W2113453730 hasConcept C3018440083 @default.
• W2113453730 hasConcept C526805850 @default.
• W2113453730 hasConcept C555283112 @default.
• W2113453730 hasConcept C71924100 @default.
• W2113453730 hasConceptScore W2113453730C121608353 @default.
• W2113453730 hasConceptScore W2113453730C126322002 @default.
• W2113453730 hasConceptScore W2113453730C134018914 @default.
• W2113453730 hasConceptScore W2113453730C147583825 @default.
• W2113453730 hasConceptScore W2113453730C2776390293 @default.
• W2113453730 hasConceptScore W2113453730C2778452354 @default.
• W2113453730 hasConceptScore W2113453730C2779107934 @default.
• W2113453730 hasConceptScore W2113453730C2780669762 @default.
• W2113453730 hasConceptScore W2113453730C3018440083 @default.
• W2113453730 hasConceptScore W2113453730C526805850 @default.

• next